AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6793373
Drug: Sublingual nitroglycerin
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerin 0.5 mg
Trial: 6793373
Drug: Oral nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral nitroglycerin 6.5 mg
Trial: 15725050
Drug: Hydrofluoroalkane metered
RxNorm normalized name: HYDROFLUOROALKANE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrofluoroalkane metered dose inhaler (HFA-MDI)
Trial: 12011296
Drug: Pramipexole (PPX)
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pramipexole (PPX) at doses of 1.5 mg/d and 4.5 mg/d
Trial: 10216808
Drug: Eprosartan +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan + Hydrochlorothiazide (HCTZ) (12.5‐25 mg o.d. added if SitDBP > or = 90 mmHg)
Trial: 2129650
Drug: ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ranitidine 150 mg b.d.
Trial: 799984
Drug: Nefopam 30
RxNorm normalized name: nefopam 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam 30 mg
Trial: 799984
Drug: Nefopam 60
RxNorm normalized name: nefopam 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam 60 mg
Trial: 23341426
Drug: Water-ethanol (95%)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Water-ethanol (95%) solution (control)
Trial: 19089448
Drug: Family-based group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-based group treatment
Trial: 9562311
Drug: Aspirin 990
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 990 mg/day + Dipyridamole 225 mg/day
Trial: 28258090
Drug: Metformin (850mg)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (850mg)
Trial: 28258090
Drug: Placebo (for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (for Metformin)
Trial: 23944945
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of FPND and FESS
Trial: 21333458
Drug: COMBOHP (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMBOHP (combination high protein diet; 0.92% creatine monohydrate and 2.75% dextrose with minimum 16% crude protein)
Trial: 21333458
Drug: COMBO (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMBO (combination diet; 0.92% creatine monohydrate and 2.75% dextrose)
Trial: 11641592
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of amphetamine combined with physiotherapy for 10 sessions over 5 weeks
Trial: 22801937
Drug: Vaginal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal estrogen therapy (estradiol, E(2)) with vaginal mesh prolapse surgery (VM)
Trial: 22801937
Drug: Vaginal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal estrogen therapy (estradiol, E(2)) with minimally invasive sacral colpopexy (MISC)
Trial: 22801937
Drug: Vaginal mesh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal mesh prolapse surgery (VM) without vaginal estrogen therapy
Trial: 22801937
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive sacral colpopexy (MISC) without vaginal estrogen therapy
Trial: 21365652
Drug: medication
RxNorm normalized name: Acne Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medication
Trial: 8606694
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate (600 mg b.i.d. x 6 days)
Trial: 1413136
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (6 g daily for four weeks)
Trial: 31204333
Drug: Capsule lycopene
RxNorm normalized name: lycopene Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule lycopene
Trial: 31204333
Drug: Capsule lycopene
RxNorm normalized name: lycopene Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule lycopene and injection dexamethasone
Trial: 31204333
Drug: Injection dexamethasone
RxNorm normalized name: dexamethasone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection dexamethasone and hyaluronidase
Trial: 24483757
Drug: nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine 20 mg Q 8‐hourly
Trial: 24483757
Drug: progesterone 400
RxNorm normalized name: progesterone 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: progesterone 400 mg daily
Trial: 22019244
Drug: Multiple kilovoltage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple kilovoltage (kV) and megavoltage (MV) imaging of implanted gold markers during treatment
Trial: 16098253
Drug: LDCI 5‐FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDCI 5‐FU 300 mg/m(2) per day for 28 days every 5 weeks
Trial: 16098253
Drug: HDI 5‐FU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDI 5‐FU 2,600 mg/m(2) for 24 hours each week
Trial: 7742151
Drug: Simvastatin (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (10-40 mg day-1 for three periods of 6 weeks)
Trial: 7742151
Drug: Pravastatin (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (10-40 mg day-1 for three periods of 6 weeks)
Trial: 2036922
Drug: Metoclopramide administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide administered intravenously every 8 hours until solid food diet tolerated
Trial: 7091898
Drug: Combined maneuvers
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined maneuvers (postural drainage, deep breathing with vibrations, and percussion) administered by a physiotherapist
Trial: 29017481
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral group therapy (STEpS)
Trial: 25910804
Drug: SR-nitrite (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR-nitrite (80 mg, twice daily by mouth for 21 days)
Trial: 17970675
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal therapy during gestation
Trial: 15496697
Drug: Midazolam 2-4
RxNorm normalized name: midazolam 2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 2-4 mg
Trial: 15496697
Drug: Etomidate 0.2-0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate 0.2-0.3 mg/kg
Trial: 11563998
Drug: Pantoprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole (20 mg)
Trial: 8065835
Drug: High-dose surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose surfactant (200 mg/kg, max 600 mg/kg)
Trial: 8065835
Drug: Low-dose surfactant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose surfactant (100 mg/kg, max 300 mg/kg)
Trial: 8065835
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment schedules (high-dose and low-dose)
Trial: 28049190
Drug: <sup>131</sup>I treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: <sup>131</sup>I treatment
Trial: 28049190
Drug: Methylprednisolone treatment
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone treatment in combination with <sup>131</sup>I treatment
Trial: 28049190
Drug: RTX in
RxNorm normalized name: RTX
DrugBank: Resiniferatoxin (DB06515)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTX in combination with <sup>131</sup>I treatment
Trial: 12777589
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 200 micro g/d (max 400 micro g/d if uncontrolled)
Trial: 12777589
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (NS) 8 mg/d (max 16 mg/d if uncontrolled)
Trial: 11127339
Drug: Rice powder
RxNorm normalized name: White rice powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice powder salt solution and milk-rice mixture (RPSS-MR group, n = 17)
Trial: 11127339
Drug: Glucose-based oral
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-based oral rehydration solution combined with milk-rice mixture (ORS-MR group, n = 17)
Trial: 11127339
Drug: Glucose-based oral
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-based oral rehydration solution combined with formula milk (ORS-milk group, n = 14)
Trial: 16709595
Drug: Diuretic use
RxNorm normalized name: benazepril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic use
Trial: 29462033
Drug: Intravenous low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous low-dose epinephrine plus tranexamic acid
Trial: 29462033
Drug: Topical diluted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diluted epinephrine plus tranexamic acid
Trial: 24343823
Drug: Therapeutic hypothermia
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic hypothermia (TH) for 72 hours, maintaining rectal temperature at 33-34°C
Trial: 19627552
Drug: Single-dose breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose breast milk
Trial: 19627552
Drug: Single-dose sterile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose sterile water
Trial: 19627552
Drug: Single-dose 12.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose 12.5% sucrose
Trial: 19627552
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses breast milk
Trial: 19627552
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses sterile water
Trial: 19627552
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses 12.5% sucrose
Trial: 11929799
Drug: Oral valacyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral valacyclovir (2 g) 4 times daily until week 18 after transplantation
Trial: 11929799
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir (800 mg) 4 times daily until week 18 after transplantation
Trial: 8546282
Drug: Intrathecal pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal pethidine hydrochloride 0.50 mg.kg‐1
Trial: 8546282
Drug: Intrathecal pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal pethidine hydrochloride 0.75 mg.kg‐1
Trial: 8546282
Drug: Isobaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isobaric bupivacaine 13.75 mg
Trial: 2468931
Drug: Intranasal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal administration of synthetic human natriuretic peptide (4‐28 hANP) at doses of 50, 100, 200, and 500 micrograms.
Trial: 2468931
Drug: Vehicle administered
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle administered randomly between doses of hANP.
Trial: 29343088
Drug: Promotion messages
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Promotion messages (e.g., 'Live your best life - Take your medications')
Trial: 29343088
Drug: Prevention messages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prevention messages (e.g., 'team up with your provider to create a combination of medications to prevent illness')
Trial: 27397061
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with fenofibrate (200 mg/day or 160 mg/day) and ezetimibe (10 mg/day)
Trial: 17076980
Drug: Ezetimibe monotherapy
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe monotherapy
Trial: 27397061
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with fenofibrate and ezetimibe
Trial: 22395779
Drug: Aminophylline (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (75 mg intravenous)
Trial: 20880999
Drug: Paclitaxel 200
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 200 mg/m² plus gemcitabine 1 gm/m² (group A) on days 1 and 8 every 3 weeks
Trial: 20880999
Drug: Paclitaxel 80
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 80 mg/m² plus vinorelbine 22.5 mg/m² (group B) on days 1, 8 and 15 every 4 weeks
Trial: 26179754
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine once-daily
Trial: 19905891
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir twice-daily
Trial: 19905891
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine once-daily and Insulin detemir twice-daily
Trial: 16846400
Drug: Tadalafil 20-mg
RxNorm normalized name: tadalafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 20-mg taken 'as needed'
Trial: 6347118
Drug: Disulfiram (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram (125 mg/day for 7 days, then 250 mg/day for 36 weeks)
Trial: 25545549
Drug: 0.1% mometasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% mometasone furoate lotion (reference)
Trial: 10443240
Drug: Tularemia live
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tularemia live vaccine (TLV) immunization given 15-20 days before surgery
Trial: 7756706
Drug: Gentamicin 6
RxNorm normalized name: gentamicin 60 mg/50 mL-0.9% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin 6 mg/kg
Trial: 26822630
Drug: Pioglitazone 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 7.5 mg daily for 8 weeks
Trial: 22232462
Drug: High-fat breakfast
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat breakfast with moxidectin (8 mg)
Trial: 22232462
Drug: Fasted subjects
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasted subjects with moxidectin (8 mg)
Trial: 20951424
Drug: RG7128 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG7128 (1000 mg twice daily) and danoprevir (900 mg twice daily)
Trial: 17949396
Drug: Murex HIV
RxNorm normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Murex HIV antigen/antibody combination enzyme immunoassay
Trial: 16117821
Drug: Methylprednisolone i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone i.v. pulses for 2 weeks followed by oral prednisone for 4 months
Trial: 10425981
Drug: Physiologic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic saline solution iontophoresis (Control)
Trial: 2339974
Drug: Hyoscine (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine (0.6 mg)
Trial: 441422
Drug: Intracervical application
RxNorm normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracervical application of 0.1, 0.2 or 0.3 mg PG‐E2 in 1 ml viscous gel
Trial: 21272047
Drug: Rabeprazole-DR 20
RxNorm normalized name: rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rabeprazole-DR 20 mg
Trial: 15134239
Drug: Oral anticoagulants
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulants (e.g., warfarin)
Trial: 15134239
Drug: Anti-vitamin K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-vitamin K drugs (warfarin)
Trial: 15134239
Drug: Prior anticoagulant
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior anticoagulant treatment before cardioversion
Trial: 2962712
Drug: 3% foscarnet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% foscarnet cream
Trial: 2962712
Drug: Placebo (cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cream vehicle)
Trial: 29943624
Drug: Sorafenib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib treatment in SHARP eligible patients
Trial: 29943624
Drug: Sorafenib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib treatment in SHARP non-eligible patients
Trial: 26480664
Drug: GLP-1 analogue
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 analogue and metformin hydrochloride
Trial: 26480664
Drug: Insulin and
RxNorm normalized name: Isophane insulin and porcine regular insulin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin and metformin hydrochloride
Trial: 21682834
Drug: Avandamet (rosiglitazone/metformin)
RxNorm normalized name: metformin hydrochloride / rosiglitazone Oral Tablet [Avandamet]
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Avandamet (rosiglitazone/metformin)
Trial: 11333290
Drug: Tamoxifen (continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (continued therapy)
Trial: 7704288
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg b.i.d for 6 weeks)
Trial: 24115478
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) administered chairside during dialysis for 3 months
Trial: 23878604
Drug: Once-weekly yoga
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly yoga classes (n = 49)
Trial: 23878604
Drug: Twice-weekly yoga
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly yoga classes (n = 46)
Trial: 21159050
Drug: Cognitive Stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Stimulation Therapy (CST) combined with donepezil, 30-minute sessions weekly for 7 weeks.
Trial: 7727669
Drug: Topical formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical formulation (15% paromomycin sulfate/5% methylbenzethonium chloride, twice a day) and injectable meglumine antimonate (20 mg of antimony [Sb]/kg.d) for 10 days and 7 days respectively
Trial: 7727669
Drug: Topical formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical formulation (15% paromomycin sulfate/5% methylbenzethonium chloride, twice a day) and injectable meglumine antimonate (20 mg of antimony [Sb]/kg.d) for 10 days and 3 days respectively
Trial: 2523657
Drug: Isradipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (2.5 to 7.5 mg twice daily)
Trial: 127945
Drug: Aqueous procaine
RxNorm normalized name: Aqueous procaine penicillin G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous procaine penicillin G, 4.8 million units intramuscularly plus 1 g of oral probenecid
Trial: 30858230
Drug: Low-trigger group
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-trigger group (hemoglobin < 8.0 g/dL)
Trial: 30858230
Drug: High-trigger group
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-trigger group (hemoglobin < 9.7 g/dL)
Trial: 25867874
Drug: Morphine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine infusion 0.02 mg/kg/h after 0.1 mg/kg iv bolus
Trial: 25867874
Drug: Remifentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil infusion 0.25 µg/kg/min following 1 µg/kg iv bolus
Trial: 25867874
Drug: Alfentanil infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil infusion 0.50 µg/kg/min following 10 µg/kg iv bolus
Trial: 25867874
Drug: Saline 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 5 cc iv bolus and 10 cc/h infusion for induction and maintenance
Trial: 17485570
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg/metformin 2,000 mg (S100/M2000)
Trial: 17485570
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg/metformin 1,000 mg (S100/M1000)
Trial: 17485570
Drug: Metformin 2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 2,000 mg (M2000)